

1 LYNN H. PASAHOW (CSB 054283)  
 (lpasahow@fenwick.com)  
 2 FENWICK & WEST LLP  
 Silicon Valley Center, 801 California Street  
 3 Mountain View, CA 940401  
 Telephone: (650) 988-8500  
 4 Facsimile: (650) 938-5200

5 Attorneys for Plaintiffs/Counterclaim-Defendants  
 THE REGENTS OF THE UNIVERSITY OF  
 6 CALIFORNIA, ABBOTT MOLECULAR INC., and  
 ABBOTT LABORATORIES INC.  
 7

8 THOMAS H. JENKINS (Admitted *Pro Hac Vice*)  
 (tom.jenkins@finnegan.com)  
 9 FINNEGAN, HENDERSON, FARABOW,  
 GARRETT & DUNNER, L.L.P.  
 10 901 New York Avenue  
 Washington D.C, 20001-4413  
 11 Telephone: (202) 408-4000  
 Facsimile: (202) 408-4400  
 12

13 Attorneys for Defendants/Counterclaim-Plaintiffs  
 DAKO NORTH AMERICA, INC. and DAKO  
 14 DENMARK A/S

15 [Additional Counsel appear on signature page]

16 UNITED STATES DISTRICT COURT  
 17 NORTHERN DISTRICT OF CALIFORNIA  
 18 SAN FRANCISCO DIVISION

19 THE REGENTS OF THE UNIVERSITY  
 OF CALIFORNIA, ABBOTT  
 20 MOLECULAR INC., and ABBOTT  
 LABORATORIES INC.,

21 Plaintiffs,

22 v.

23 DAKO NORTH AMERICA, INC. and  
 24 DAKO DENMARK A/S,

25 Defendants.

Case No. C 05-03955 MHP

**STIPULATION AND ~~PROPOSED~~ ORDER  
 RE SUPPLEMENTAL CLAIM  
 CONSTRUCTION**

The Honorable Marilyn Hall Patel

26 AND RELATED COUNTERCLAIMS.  
 27

1 WHEREAS, hearing on the parties' supplemental claim construction briefing on the  
2 proper construction of "blocking nucleic acid" is currently scheduled for April 23, 2009;

3 WHEREAS, the parties have since met and conferred and agree to a construction of  
4 "blocking nucleic acid";

5 Plaintiffs The Regents of the University of California, Abbott Molecular Inc. and Abbott  
6 Laboratories Inc. ("plaintiffs") and defendants Dako North America, Inc. and Dako Denmark A/S  
7 ("Dako") hereby stipulate as follows:

8 1) The parties agree that "blocking nucleic acid" should be construed to mean  
9 "nucleic acid used to prevent hybridization of repetitive sequences in the labeled nucleic acid to  
10 the chromosomal DNA";

11 2) The hearing on the parties' supplemental claim construction briefing scheduled for  
12 April 23, 2009 is made moot by this construction and is therefore taken off-calendar;

13 3) The hearing on Dako's Motion for Partial Summary Judgment of Noninfringement  
14 (Docket No. 269) scheduled for April 23, 2009 is made moot by this construction and is therefore  
15 taken off-calendar;

16 4) The hearing on Plaintiffs' Motion for Summary Judgment of Infringement (Docket  
17 No. 265) and Dako's Motion in Limine to Exclude Testimony of Mark E. Nusbaum (Docket No.  
18 276) also scheduled for April 23, 2009 will proceed;

19 5) Dako will have until April 17, 2009 to amend the Expert Report of Robert H.  
20 Singer, Ph.D. ("Singer Report") to address the amended construction of "blocking nucleic acid."  
21 Any amendment to the Singer Report will be limited to Dr. Singer's opinions regarding written  
22 description and enablement under 35 U.S.C. § 112 ¶ 1 that arise solely because of the amendment  
23 to the construction of "blocking nucleic acid." Specifically, any amendment will be limited to  
24 addressing any written description or enablement argument that arises from the difference in the  
25 scope of an invention that covers use of "repetitive-sequence-enriched DNA or RNA" and an  
26 invention that covers use of "nucleic acid used to prevent hybridization of repetitive sequences in  
27 the labeled nucleic acid to the chromosomal DNA." No other amendment to the Singer Report is  
28 allowed by this stipulation;

1           6)       The parties agree that the opinions in the Expert Report of Dr. James Coull (“Coull  
2 Report”) that the use of PNA in the accused *HER2* and *TOP2A* is not equivalent to the use of  
3 “blocking nucleic acid” as claimed in the ’841 patent shall apply as well to the use of PNA in  
4 Dako’s other accused products;

5           7)       Plaintiffs will have until May 1, 2009 to amend the Rebuttal Expert Report of Dr.  
6 Mary E. Harper (“Harper Rebuttal Report”) to respond to any amendments to the Singer Report;

7           8)       Dako will make Dr. Singer available to plaintiffs for deposition to address any  
8 amendment to the Singer Report. Plaintiffs will make Dr. Harper available for a supplemental  
9 deposition if plaintiffs re-depose Dr. Singer;

10          9)       Any amendment to the parties’ expert reports will have no effect on motions for  
11 summary judgment. Specifically, any amendment to the Singer Report or the Harper Rebuttal  
12 Report will not be used to supplement any of the parties’ pending motions for summary  
13 judgment. Nor will any amendment to the Singer Report or the Harper Rebuttal Report be used  
14 as a basis to bring any new motion for summary judgment;

15          10)      Neither party will contend that this stipulation or any action taken pursuant to it  
16 supports any change to the existing pretrial or trial schedule other than as provided herein.



1 Dated: April 9, 2009

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

2  
3 By: Tina E. Hulse  
Tina E. Hulse

4 THOMAS H. JENKINS (Admitted *Pro Hac Vice*)  
(tom.jenkins@finnegan.com)  
5 ANTHONY C. TRIDICO (Admitted *Pro Hac Vice*)  
(anthony.tridico@finnegan.com)  
6 FINNEGAN, HENDERSON, FARABOW,  
7 GARRETT & DUNNER, L.L.P.  
901 New York Avenue  
8 Washington, D.C. 20001-4413  
Telephone: (202) 408-4000  
9 Facsimile: (202) 408-4400

10 Tina E. Hulse (CA Bar No. 232936)  
(tina.hulse@finnegan.com)  
11 Wesley Derrick (CA Bar No. 244944)  
(wesley.derrick@finnegan.com)  
12 Sarah E. Craven (CA Bar No. 261046)  
(sarah.craven@finnegan.com)  
13 FINNEGAN, HENDERSON, FARABOW,  
14 GARRETT & DUNNER, L.L.P.  
Stanford Research Park  
3300 Hillview Avenue  
15 Palo Alto, California 94304  
Telephone: (650) 849-6600  
16 Facsimile: (650) 849-6666

17 Attorneys for Defendants/Counterclaim-Plaintiffs  
18 DAKO NORTH AMERICA, INC. and DAKO  
19 DENMARK A/S  
20  
21  
22  
23  
24  
25  
26  
27  
28

1 **ORDER**

2 Pursuant to the foregoing Stipulation, and good cause appearing, the Court hereby orders  
3 as follows:

4 1) The parties agree that “blocking nucleic acid” should be construed to mean  
5 “nucleic acid used to prevent hybridization of repetitive sequences in the labeled nucleic acid to  
6 the chromosomal DNA”;

7 2) The hearing on the parties’ supplemental claim construction briefing scheduled for  
8 April 23, 2009 is made moot by this construction and is therefore taken off-calendar;

9 3) The hearing on Dako’s Motion for Partial Summary Judgment of Noninfringement  
10 (Docket No. 269) scheduled for April 23, 2009 is made moot by this construction and is therefore  
11 taken off-calendar;

12 4) The hearing on Plaintiffs’ Motion for Summary Judgment of Infringement (Docket  
13 No. 265) and Dako’s Motion in Limine to Exclude Testimony of Mark E. Nusbaum (Docket No.  
14 276) also scheduled for April 23, 2009 will proceed;

15 5) Dako will have until April 17, 2009 to amend the Expert Report of Robert H.  
16 Singer, Ph.D. (“Singer Report”) to address the amended construction of “blocking nucleic acid.”  
17 Any amendment to the Singer Report will be limited to Dr. Singer’s opinions regarding written  
18 description and enablement under 35 U.S.C. § 112 ¶ 1 that arise solely because of the amendment  
19 to the construction of “blocking nucleic acid.” Specifically, any amendment will be limited to  
20 addressing any written description or enablement argument that arises from the difference in the  
21 scope of an invention that covers use of “repetitive-sequence-enriched DNA or RNA” and an  
22 invention that covers use of “nucleic acid used to prevent hybridization of repetitive sequences in  
23 the labeled nucleic acid to the chromosomal DNA.” No other amendment to the Singer Report is  
24 allowed by this stipulation;

25 6) The parties agree that the opinions in the Expert Report of Dr. James Coull (“Coull  
26 Report”) that the use of PNA in the accused *HER2* and *TOP2A* is not equivalent to the use of  
27 “blocking nucleic acid” as claimed in the ’841 patent shall apply as well to the use of PNA in  
28 Dako’s other accused products;

1           7)       Plaintiffs will have until May 1, 2009 to amend the Rebuttal Expert Report of Dr.  
2 Mary E. Harper (“Harper Rebuttal Report”) to respond to any amendments to the Singer Report;

3           8)       Dako will make Dr. Singer available to plaintiffs for deposition to address any  
4 amendment to the Singer Report. Plaintiffs will make Dr. Harper available for a supplemental  
5 deposition if plaintiffs re-depose Dr. Singer;

6           9)       Any amendment to the parties’ expert reports will have no effect on motions for  
7 summary judgment. Specifically, any amendment to the Singer Report or the Harper Rebuttal  
8 Report will not be used to supplement any of the parties’ pending motions for summary  
9 judgment. Nor will any amendment to the Singer Report or the Harper Rebuttal Report be used  
10 as a basis to bring any new motion for summary judgment;

11          10)      Except as provided in this order, the pretrial and trial schedule previously  
12 established remains in effect.

13                   **IT IS SO ORDERED.**

14  
15 Dated:   4/13  , 2009

